Amyloid Solution Inc. is a pioneering biotech company at the forefront of discovering disease-modifying targets and developing novel drug candidates, including small molecules and other innovative modalities, for the treatment of Alzheimer’s disease (AD). While antibody-based treatments targeting Aβ have been approved for AD, they come with significant challenges, including side effect like microhemorrhage and edema (ARIA), and still need improvement, particularly in enhancing cognitive benefits. There is also a growing consensus on the critical importance of Tau regulation to improve cognitive outcomes. Although developing small molecule therapeutics that directly bind and modulate both Aβ and Tau is highly desirable, it remains a complex challenge. Our company is advancing a first-in-class small molecule therapy that dual targets Aβ and Tau, effectively dissociating aggregates into monomers. This treatment is designed to cross the blood-brain barrier efficiently, regulate both extracellular and intracellular Aβ and Tau, and demonstrate both safety and efficacy. We are poised to enter Phase 1 clinical trials soon. This approach also holds promise for the development of small molecules targeting other misfolded proteins, enabling us to expand our pipeline to address a broader range of neurodegenerative diseases. In addition, we are developing first-in-class therapies aimed at normalizing the functions of glia and lysosomes. Currently based in South Korea, we are actively exploring opportunities for global expansion.